Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Novel pharmacological approaches to modulate protein synthesis and improve cancer outcome

FY 2013-14

Summary
Protein synthesis, or the translation of mRNA, is dysregulated in cancer. The altered activity of the eukaryotic initiation factor 4E (eIF4E), a critical translation factor, has been shown to promote cancer development. Recently it has been shown that the phosphorylation of eIF4E is essential in mediating its pro-oncogenic effects, and in promoting the progression of cancer to metastasis. Therefore, targeting the phosphorylation of eIF4E represents an increasingly attractive therapeutic avenue to correct the dysregulation of translation in cancer. We hypothesis that therapeutic inhibitors of eIF4E phosphorylation can improve cancer outcome. Since currently available inhibitors of eIF4E phosphorylation have limited value, we will identify new drugs that prevent eIF4E phosphorylation, and characterize their therapeutic efficacy in an effort to optimize cancer treatments. As part of the eIF4G complex, eIF4E binds the mRNA cap structure. The interaction of mRNA transcripts with the ribosome, which carries out protein synthesis, is facilitated by eIF4G. Transcripts known to encode proteins promoting cancer, are particularly sensitive to eIF4E expression and activity. Importantly, overexpression of eIF4E occurs in 30% of human cancers and has been attributed to poor prognosis. Fine regulation of eIF4E is achieved via phosphorylation by MAP kinase-interacting kinases 1/2 (Mnks). Upon MAP Kinase pathway activation by common stimuli, MNK1 docks onto the scaffolding protein eIF4G to gain access to eIF4E. Phosphorylation of eIF4E preferentially stimulates translation of a subset of transcripts required for tumor development, growth, and metastasis. Furthermore, eIF4E phosphorylation is elevated in many human cancers and mice which cannot phosphorylate eIF4E are resistant to prostate cancer development and mammary tumor onset, demonstrating the critical role of phosphorylation in the oncogenic potential of eIF4E. Recently, eIF4E phosphorylation has been implicated as a factor promoting metastasis in a mouse model of breast cancer and identified in mechanisms of resistance to common chemotherapeutics, such as Herceptin. There are currently no inhibitors of eIF4E phosphorylation being developed for clinical use. A high-throughput assay to identify inhibitors of eIF4E phosphorylation will be developed. The structures of MNK1 and eIF4G have been described and their interacting domains have been established. The readout for this assay will be a fluorescent signal produced only when MNK1 and eIF4G are in close proximity and therefore in complex. In a high-throughput screen, 7000 compounds designed to mimic protein-protein interaction surfaces will be tested for interference with the eIF4G-MNK complex and therefore disruption of the fluorescent signal. This strategy targets eIF4G-MNK1 interaction, eliminating non-specific effects associated with targeting upstream kinases. The efficacy and specificity of any identified compounds will be tested in cell culture based experiments on proliferation, apoptosis, focus formation, anchorage independent growth and invasion. The most promising hits will be selected for evaluation in mouse models of metastatic breast cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311759
Name
Hearnden Jaclyn
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel pharmacological approaches to modulate protein synthesis and improve cancer outcome
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Drugs; Kinase; Metastasis; Novel; Phosphorylation; Screen; Therapy; Translation; Treatment
Abstract
Protein synthesis, or the translation of mRNA, is dysregulated in cancer. The altered activity of the eukaryotic initiation factor 4E (eIF4E), a critical translation factor, has been shown to promote cancer development. Recently it has been shown that the phosphorylation of eIF4E is essential in mediating its pro-oncogenic effects, and in promoting the progression of cancer to metastasis. Therefore, targeting the phosphorylation of eIF4E represents an increasingly attractive therapeutic avenue to correct the dysregulation of translation in cancer. We hypothesis that therapeutic inhibitors of eIF4E phosphorylation can improve cancer outcome. Since currently available inhibitors of eIF4E phosphorylation have limited value, we will identify new drugs that prevent eIF4E phosphorylation, and characterize their therapeutic efficacy in an effort to optimize cancer treatments. As part of the eIF4G complex, eIF4E binds the mRNA cap structure. The interaction of mRNA transcripts with the ribosome, which carries out protein synthesis, is facilitated by eIF4G. Transcripts known to encode proteins promoting cancer, are particularly sensitive to eIF4E expression and activity. Importantly, overexpression of eIF4E occurs in 30% of human cancers and has been attributed to poor prognosis. Fine regulation of eIF4E is achieved via phosphorylation by MAP kinase-interacting kinases 1/2 (Mnks). Upon MAP Kinase pathway activation by common stimuli, MNK1 docks onto the scaffolding protein eIF4G to gain access to eIF4E. Phosphorylation of eIF4E preferentially stimulates translation of a subset of transcripts required for tumor development, growth, and metastasis. Furthermore, eIF4E phosphorylation is elevated in many human cancers and mice which cannot phosphorylate eIF4E are resistant to prostate cancer development and mammary tumor onset, demonstrating the critical role of phosphorylation in the oncogenic potential of eIF4E. Recently, eIF4E phosphorylation has been implicated as a factor promoting metastasis in a mouse model of breast cancer and identified in mechanisms of resistance to common chemotherapeutics, such as Herceptin. There are currently no inhibitors of eIF4E phosphorylation being developed for clinical use. A high-throughput assay to identify inhibitors of eIF4E phosphorylation will be developed. The structures of MNK1 and eIF4G have been described and their interacting domains have been established. The readout for this assay will be a fluorescent signal produced only when MNK1 and eIF4G are in close proximity and therefore in complex. In a high-throughput screen, 7000 compounds designed to mimic protein-protein interaction surfaces will be tested for interference with the eIF4G-MNK complex and therefore disruption of the fluorescent signal. This strategy targets eIF4G-MNK1 interaction, eliminating non-specific effects associated with targeting upstream kinases. The efficacy and specificity of any identified compounds will be tested in cell culture based experiments on proliferation, apoptosis, focus formation, anchorage independent growth and invasion. The most promising hits will be selected for evaluation in mouse models of metastatic breast cancer.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hearnden, Jaclyn
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~